CCL2 and diabetic kidney disease: Thus, not surprisingly, urinary MCP-1 has been suggested as a diagnostic marker for progressive renal injury in diabetic nephropathy [34,42], and pharmacological targeting of MCP-1 and its receptor CCR2 has been proposed as a novel approach to treat diabetic kidney disease [43,44].